Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 3/20 | 0.53 |
| ▸ | JAK2 | O60674 | 3/20 | 0.48 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | NUDT1 | P36639 | 4/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.42 |
| ▸ | CLK2 | P49760 | 3/20 | 0.42 |
| ▸ | CLK3 | P49761 | 2/20 | 0.42 |
| ▸ | WNT1 | P04628 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 3/20 | 0.39 |
| ▸ | BCR | P11274 | 3/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | KDM5A | P29375 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31420127 | 1.00 | TBK1 (0.53) | TBK1JAK2BTKNUDT1DYRK1A | |
| SCHEMBL30633298 | 0.91 | TBK1 (0.55) | TBK1JAK2DYRK1ACLK2CLK3 | |
| SCHEMBL26685843 | 0.91 | TBK1 (0.55) | TBK1JAK2DYRK1ACLK2CLK3 | |
| SCHEMBL26686408 | 0.84 | NUDT1 (0.48) | JAK2NUDT1DYRK1ACLK2CLK3 | |
| SCHEMBL26685791 | 0.84 | NUDT1 (0.60) | JAK2NUDT1DYRK1ACLK2CLK3 | |
| SCHEMBL31240425 | 0.84 | NUDT1 (0.48) | JAK2NUDT1DYRK1ACLK2CLK3 | |
| SCHEMBL31420159 | 0.84 | NUDT1 (0.60) | JAK2NUDT1DYRK1ACLK2CLK3 | |
| SCHEMBL30633374 | 0.82 | DYRK1A (0.56) | NUDT1DYRK1ACLK2CLK3WNT1 | |
| SCHEMBL26686261 | 0.82 | DYRK1A (0.56) | NUDT1DYRK1ACLK2CLK3WNT1 | |
| SCHEMBL30633398 | 0.81 | NUDT1 (0.46) | JAK2NUDT1DYRK1ACLK2CLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705291-A1 | IKK-ALPHA INHIBITORS | Cancer Research Technology Limited (GB) | 2026-03-11 | — | — | EP | claimed |
| US-20250304576-A1 | IKK INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2025-10-02 | — | — | US | claimed |
| EP-4522597-A1 | IKK INHIBITORS | Cancer Research Technology Limited (GB) | 2025-03-19 | — | — | EP | claimed |
| WO-2024228035-A1 | IKK-ALPHA INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-11-07 | — | — | WO | claimed |
| WO-2023218201-A1 | IKK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-11-16 | — | — | WO | claimed |
| EP-4705291-A1 | IKK-ALPHA INHIBITORS | Cancer Research Technology Limited (GB) | 2026-03-11 | — | — | EP | disclosed |
| US-20250304576-A1 | IKK INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2025-10-02 | — | — | US | disclosed |
| EP-4522597-A1 | IKK INHIBITORS | Cancer Research Technology Limited (GB) | 2025-03-19 | — | — | EP | disclosed |
| WO-2024228035-A1 | IKK-ALPHA INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-11-07 | — | — | WO | disclosed |
| WO-2023218201-A1 | IKK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023218201-A1 | IKK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304576-A1 | IKK INHIBITORS | NFKBIA, IKBKE, IKBKB | TBK1 11/4885JAK2 207/4885BTK 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.